WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 30, 2026, to shareholders of record at the close of business on August 14, 2026. About Teleflex Incorporated As a global provider of medical technologies, Teleflex i...
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 30, 2026. Second quarter 2026 continuing operations financial summary1 Revenue from continuing operations of $570.3 million, up 28.9% compared to the prior year period, and up 4.7% on a pro forma adjusted constant currency basis1,2 GAAP diluted EPS f...
Combining leading in-house expertise with platform-enhancing investments to accelerate advances in engineering, innovation and manufacturing capabilities serving global medical device innovators Marks completion of acquisition by Montagu and Kohlberg PLYMOUTH, Minn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- INGENYX, formerly Teleflex Medical OEM, today announced its launch as an independent company fo...
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced it has completed the previously disclosed divestiture of its OEM business to Montagu and Kohlberg, for $1.5 billion in cash. The close of the OEM transaction marks a pivotal milestone in Teleflex's transformation strategy, sharpening the Company's focus on the commer...
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has received Biologics License Application (BLA) approval for EZPLAZ™ Freeze Dried Plasma (FDP) from the U.S. Food and Drug Administration (FDA). EZPLAZ™ FDP is approved for transfusion in adults with bleeding-related conditions requiring replacement of plasma co...
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) has been awarded a national group purchasing agreement for central venous access products with Premier, Inc. Effective July 1, 2026, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for select Teleflex products, including short-term central venous...
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2025 Global Impact Report. The report outlines recent accomplishments and future plans to support the Company's Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative (GRI), the Sustainability Accou...